Table 2.

Grouping of antiretroviral drugs for design of regimens for treatment of HIV

Group	Antiretroviral drugs
Nucleoside reverse-transcriptase inhibitors	Zidovudine (Azt/Zdv); stavudine (d4T); lamivudine (3TC); abacavir (Abc); didanosine (ddl); zalcitabine (ddC); emtricitabine (FTC)
Nucleotide reverse-transcriptase inhibitors	Tenofovir (TDF)
Non–nucleoside reverse-transcriptase inhibitors	Nevirapine (Nvp); efavirenz (Efv); delavirdine (Dlv); rilpivirine (Rpv); eltravirine (Etv)
Protease inhibitors	Saquinavir (Sqv); ritonavir (Rtv); nelfinavir (Nfv); amprenavir (Apv); indinavir (Inv); lopinavir (Lpv); fosamprenavir (Fpv); atazanavir (Atv); tipranavir (Tpv); darunavir (Drv)
Integrase strand–transferase inhibitors	Raltegravir (Rgv); elvitegravir (Evg); dolutegravir (Dtg)
Fusion inhibitors	Enfuviritide (T20)
CCR5 entry inhibitor	Maraviroc